These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 30053080)

  • 21. Timing of Radioactive Iodine Administration Does Not Influence Outcomes in Patients with Differentiated Thyroid Carcinoma.
    Scheffel RS; Zanella AB; Dora JM; Maia AL
    Thyroid; 2016 Nov; 26(11):1623-1629. PubMed ID: 27549175
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting Novel Sodium Iodide Symporter Interactors ADP-Ribosylation Factor 4 and Valosin-Containing Protein Enhances Radioiodine Uptake.
    Fletcher A; Read ML; Thornton CEM; Larner DP; Poole VL; Brookes K; Nieto HR; Alshahrani M; Thompson RJ; Lavery GG; Landa I; Fagin JA; Campbell MJ; Boelaert K; Turnell AS; Smith VE; McCabe CJ
    Cancer Res; 2020 Jan; 80(1):102-115. PubMed ID: 31672844
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients.
    Schvartz C; Bonnetain F; Dabakuyo S; Gauthier M; Cueff A; Fieffé S; Pochart JM; Cochet I; Crevisy E; Dalac A; Papathanassiou D; Toubeau M
    J Clin Endocrinol Metab; 2012 May; 97(5):1526-35. PubMed ID: 22344193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of radioiodine therapy for treating 20 patients with pulmonary metastases from differentiated thyroid cancer and a meta-analysis of the current literature.
    Zhang X; Liu DS; Luan ZS; Zhang F; Liu XH; Zhou W; Zhong SF; Lai H
    Clin Transl Oncol; 2018 Jul; 20(7):928-935. PubMed ID: 29119458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estimation of Second Primary Cancer Risk After Treatment with Radioactive Iodine for Differentiated Thyroid Carcinoma.
    Corrêa NL; de Sá LV; de Mello RC
    Thyroid; 2017 Feb; 27(2):261-270. PubMed ID: 27762670
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of Combination Therapy with Lenvatinib and Radioactive Iodine in Thyroid Cancer Preclinical Model.
    Suzuki K; Iwai H; Utsunomiya K; Kono Y; Watabe T; Kobayashi Y; Bui DV; Sawada S; Yun Y; Mitani A; Fukui K; Sakai H; Chu HH; Linh NM; Tanigawa N; Kanda A
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077268
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differentiated thyroid cancer theranostics: radioiodine and beyond.
    Choudhury PS; Gupta M
    Br J Radiol; 2018 Nov; 91(1091):20180136. PubMed ID: 30260232
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of evidence-based guidelines reduces radioactive iodine treatment in patients with low-risk differentiated thyroid cancer.
    Sacks W; Wong RM; Bresee C; Braunstein GD
    Thyroid; 2015 Apr; 25(4):377-85. PubMed ID: 25578116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Curcumin enhances the membrane trafficking of the sodium iodide symporter and augments radioiodine uptake in dedifferentiated thyroid cancer cells
    Zhang L; Xu S; Cheng X; Wu J; Wang X; Wu L; Yu H; Bao J
    Food Funct; 2021 Sep; 12(18):8260-8273. PubMed ID: 34323243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunohistochemical analysis of sodium iodide symporter expression in metastatic differentiated thyroid cancer: correlation with radioiodine uptake.
    Castro MR; Bergert ER; Goellner JR; Hay ID; Morris JC
    J Clin Endocrinol Metab; 2001 Nov; 86(11):5627-32. PubMed ID: 11701745
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma.
    Bhattacharyya N; Chien W
    Ann Otol Rhinol Laryngol; 2006 Aug; 115(8):607-10. PubMed ID: 16944659
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radioiodine-Refractory Thyroid Cancer: Molecular Basis of Redifferentiation Therapies, Management, and Novel Therapies.
    Aashiq M; Silverman DA; Na'ara S; Takahashi H; Amit M
    Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31533238
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radioactive iodine ablation does not prevent recurrences in patients with papillary thyroid microcarcinoma.
    Kim HJ; Kim NK; Choi JH; Kim SW; Jin SM; Suh S; Bae JC; Min YK; Chung JH; Kim SW
    Clin Endocrinol (Oxf); 2013 Apr; 78(4):614-20. PubMed ID: 22957654
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pregnancy outcome after diagnosis of differentiated thyroid carcinoma: no deleterious effect after radioactive iodine treatment.
    Chow SM; Yau S; Lee SH; Leung WM; Law SC
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):992-1000. PubMed ID: 15234032
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low expression of sodium iodide symporter identifies aggressive thyroid tumors.
    Ward LS; Santarosa PL; Granja F; da Assumpção LV; Savoldi M; Goldman GH
    Cancer Lett; 2003 Oct; 200(1):85-91. PubMed ID: 14550956
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients.
    Castagna MG; Cevenini G; Theodoropoulou A; Maino F; Memmo S; Claudia C; Belardini V; Brianzoni E; Pacini F
    Eur J Endocrinol; 2013 Jul; 169(1):23-9. PubMed ID: 23594687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of romidepsin for clinical activity and radioactive iodine reuptake in radioactive iodine-refractory thyroid carcinoma.
    Sherman EJ; Su YB; Lyall A; Schöder H; Fury MG; Ghossein RA; Haque S; Lisa D; Shaha AR; Tuttle RM; Pfister DG
    Thyroid; 2013 May; 23(5):593-9. PubMed ID: 23186033
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glycosylation of Sodium/Iodide Symporter (NIS) Regulates Its Membrane Translocation and Radioiodine Uptake.
    Chung T; Youn H; Yeom CJ; Kang KW; Chung JK
    PLoS One; 2015; 10(11):e0142984. PubMed ID: 26599396
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Manipulation of PBF/PTTG1IP phosphorylation status; a potential new therapeutic strategy for improving radioiodine uptake in thyroid and other tumors.
    Smith VE; Sharma N; Watkins RJ; Read ML; Ryan GA; Kwan PP; Martin A; Watkinson JC; Boelaert K; Franklyn JA; McCabe CJ
    J Clin Endocrinol Metab; 2013 Jul; 98(7):2876-86. PubMed ID: 23678037
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Determining patient selection tool and response predictor for outpatient 30 mCi radioiodine ablation dose in non-metastatic differentiated thyroid carcinoma: a Japanese perspective.
    Higuchi T; Achmad A; Binh DD; Bhattarai A; Tsushima Y
    Endocr J; 2018 Mar; 65(3):345-357. PubMed ID: 29343651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.